Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cytokinetics, Inc.

http://www.cytokinetics.com

Latest From Cytokinetics, Inc.

Cytokinetics’ Failure In ALS Clears Way For Focus On Aficamten

With a data monitoring committee finding no signs of efficacy in a Phase III trial of ALS candidate reldesemtiv, Cytokinetics can conserve cash and center on aficamten for hypertrophic cardiomyopathy.

Clinical Trials Business Strategies

BMS Advances Cardiovascular Growth Plans With Milvexian, Camzyos Milestones

Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.

Clinical Trials Strategy

Lessons Still To Learn: Cytokinetics’ Omecamtiv Is Over In The US, But FDA Debriefs Could Inform European Strategy

Cytokinetics will not conduct the new trial in heart failure with reduced ejection fraction (HFrEF) required by the FDA’s complete response letter for omecamtiv mecarbil.

US FDA Performance Tracker Rare Diseases

Keeping Track: Opdivo, Keytruda Continue Adjuvant Push As Cancer Dominates Recent Applications

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Cancer US FDA Performance Tracker
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register